Merck KGaA Acquires Rights to PI-2301 Program for Multiple Sclerosis
“Over the years we have continuously worked on developing innovative treatment options that meet the individual needs of people living with multiple sclerosis,” said Susan Herbert, Head of Global Portfolio Development at the Merck Serono division. “We are pleased to strengthen our development pipeline with the PI-2301 compound, which could play a valuable role in the treatment of this debilitating disease.”
The acquisition of PI-2301 covers its worldwide exclusive development and commercialization rights.
PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system. Merck will investigate the application of this product in autoimmune diseases such as multiple sclerosis.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.